Prognostic Utility of Early Plasma Matrix Metalloproteinases -2 and -9 Concentrations After Severe Traumatic Brain Injury

Overview

Journal Rev Bras Ter Intensiva

Specialties Critical Care
General Medicine

Date 2020 Oct 14

PMID 33053032

Citations 6

Authors

Rosane de Lima

Daniel Simon

Willy Deivson Leandro da Silva

Debora Dreher Nabinger

Andrea Regner

Affiliations

Soon will be listed here.

Abstract

Objective: To determine whether the matrix metalloproteinases-2 and -9 plasma levels were associated with intensive care unit mortality in patients who suffered severe traumatic brain injury, despite the presence of extracerebral injuries.

Methods: This prospective cohort enrolled 39 male patients who suffered severe traumatic brain injury (Glasgow coma scale: 3 - 8 at hospital admission). The plasma matrix metalloproteinase -2 and matix metalloproteinase -9 levels were determined by ELISA at the time of intensive care unit admission.

Results: Severe traumatic brain injury was associated with a 46% intensive care unit mortality rate. Higher plasma matrix metalloproteinase -9 concentrations were associated with mortality: 147.94 ± 18.00ng/mL for survivors and 224.23 ± 23.86ng/mL for nonsurvivors (mean ± standard error of the mean, p = 0.022). In contrast, there was no significant association between matrix metalloproteinase -2 levels and intensive care unit mortality: 315.68 ± 22.90ng/mL for survivors and 336.55 ± 24.29ng/mL for nonsurvivors (p = 0.499). Additionally, there were no significant associations between matrix metalloproteinase -2 (p = 0.711) and matrix metalloproteinase -9 (p = 0.092) levels and the presence of associated lesions.

Conclusion: Increased plasma matrix metalloproteinase -9 levels were associated with intensive care unit mortality following severe traumatic brain injury, regardless of the presence of extracerebral injuries. Conversely, in this same context, plasma matrix metalloproteinase -2 levels were not associated with short-term fatal outcome prediction.

Citing Articles

Topical application of daphnetin hydrogel for traumatic brain injury.

Ma Y, Liu Y, Guo J, Chen Z, Zhao Z, Zheng J Front Neurosci. 2024; 18:1450072.

PMID: 39170676 PMC: 11335657. DOI: 10.3389/fnins.2024.1450072.

The Role of S100b Protein Biomarker in Brain Death: A Literature Review.

Lopes A, Regner A, Simon D Cureus. 2024; 16(6):e62707.

PMID: 39036258 PMC: 11259197. DOI: 10.7759/cureus.62707.

'Comprehensive review of emerging drug targets in traumatic brain injury (TBI): challenges and future scope.

Banderwal R, Kadian M, Garg S, Kumar A Inflammopharmacology. 2024; 32(5):3271-3293.

PMID: 39023681 DOI: 10.1007/s10787-024-01524-w.

Time trajectories and within-subject correlations of matrix metalloproteinases 3, 8, 9, 10, 12, and 13 serum levels and their ability to predict mortality in polytraumatized patients: a pilot study.

Negrin L, Carlin G, Ristl R, Hajdu S Eur J Med Res. 2024; 29(1):225.

PMID: 38594750 PMC: 11005259. DOI: 10.1186/s40001-024-01775-x.

Developmental Regulation of Matrix Metalloproteinases in Response to Multifactorial, Severe Traumatic Brain Injuries during Immaturity.

Hochstetler A, Price G, Baohan A, Li M, Rodriguez Lara F, Lok J Dev Neurosci. 2024; 46(5):319-332.

PMID: 38190820 PMC: 11228128. DOI: 10.1159/000536054.

References

Mori T, Wang X, Aoki T, Lo E . Downregulation of matrix metalloproteinase-9 and attenuation of edema via inhibition of ERK mitogen activated protein kinase in traumatic brain injury. J Neurotrauma. 2002; 19(11):1411-9. DOI: 10.1089/089771502320914642. View

Morganti-Kossmann M, Satgunaseelan L, Bye N, Kossmann T . Modulation of immune response by head injury. Injury. 2007; 38(12):1392-400. DOI: 10.1016/j.injury.2007.10.005. View

Kim J, Kim N, Zheng Z, Lee J, Yenari M . The 70 kDa heat shock protein protects against experimental traumatic brain injury. Neurobiol Dis. 2013; 58:289-95. PMC: 3799906. DOI: 10.1016/j.nbd.2013.06.012. View

Filho E, Simon D, Ikuta N, Klovan C, Dannebrock F, Oliveira C . Elevated cell-free plasma DNA level as an independent predictor of mortality in patients with severe traumatic brain injury. J Neurotrauma. 2014; 31(19):1639-46. PMC: 4171115. DOI: 10.1089/neu.2013.3178. View

Shi W, Ju J, Xiao H, Xue F, Wu J, Pan M . Dynamics of MMP‑9, MMP‑2 and TIMP‑1 in a rat model of brain injury combined with traumatic heterotopic ossification. Mol Med Rep. 2017; 15(4):2129-2135. PMC: 5365022. DOI: 10.3892/mmr.2017.6275. View

Coronado V, Xu L, Basavaraju S, McGuire L, Wald M, Faul M . Surveillance for traumatic brain injury-related deaths--United States, 1997-2007. MMWR Surveill Summ. 2011; 60(5):1-32. View

Underly R, Levy M, Hartmann D, Grant R, Watson A, Shih A . Pericytes as Inducers of Rapid, Matrix Metalloproteinase-9-Dependent Capillary Damage during Ischemia. J Neurosci. 2017; 37(1):129-140. PMC: 5214626. DOI: 10.1523/JNEUROSCI.2891-16.2016. View

Gottschall P, Yu X, BING B . Increased production of gelatinase B (matrix metalloproteinase-9) and interleukin-6 by activated rat microglia in culture. J Neurosci Res. 1995; 42(3):335-42. DOI: 10.1002/jnr.490420307. View

Vilalta A, Sahuquillo J, Rosell A, Poca M, Riveiro M, Montaner J . Moderate and severe traumatic brain injury induce early overexpression of systemic and brain gelatinases. Intensive Care Med. 2008; 34(8):1384-92. DOI: 10.1007/s00134-008-1056-1. View

10.

Harkness K, Adamson P, Sussman J, DAVIES-JONES G, Greenwood J, Woodroofe M . Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium. Brain. 2000; 123 ( Pt 4):698-709. DOI: 10.1093/brain/123.4.698. View

11.

Danilina T, Silachev D, Pevzner I, Gulyaev M, Pirogov Y, Zorova L . The Influence of Proinflammatory Factors on the Neuroprotective Efficiency of Multipotent Mesenchymal Stromal Cells in Traumatic Brain Injury. Bull Exp Biol Med. 2017; 163(4):528-534. DOI: 10.1007/s10517-017-3844-5. View

12.

Liu C, Chen C, Lee H, Cho D . Matrix metalloproteinase-9 in the ventricular cerebrospinal fluid correlated with the prognosis of traumatic brain injury. Turk Neurosurg. 2014; 24(3):363-8. DOI: 10.5137/1019-5149.JTN.8551-13.0. View

13.

REGNER A, Kaufman M, Friedman G, Chemale I . Increased serum S100beta protein concentrations following severe head injury in humans: a biochemical marker of brain death?. Neuroreport. 2001; 12(4):691-4. DOI: 10.1097/00001756-200103260-00015. View

14.

Simon D, Evaldt J, Nabinger D, Fontana M, Klein M, Gomes J . Plasma matrix metalloproteinase-9 levels predict intensive care unit mortality early after severe traumatic brain injury. Brain Inj. 2017; 31(3):390-395. DOI: 10.1080/02699052.2016.1259501. View

15.

Vajtr D, Benada O, Kukacka J, Prusa R, Houstava L, Toupalik P . Correlation of ultrastructural changes of endothelial cells and astrocytes occurring during blood brain barrier damage after traumatic brain injury with biochemical markers of BBB leakage and inflammatory response. Physiol Res. 2008; 58(2):263-268. DOI: 10.33549/physiolres.931253. View

16.

Hadass O, Tomlinson B, Gooyit M, Chen S, Purdy J, Walker J . Selective inhibition of matrix metalloproteinase-9 attenuates secondary damage resulting from severe traumatic brain injury. PLoS One. 2013; 8(10):e76904. PMC: 3806745. DOI: 10.1371/journal.pone.0076904. View

17.

Alvarez-Sabin J, Delgado P, Abilleira S, Molina C, Arenillas J, Ribo M . Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome. Stroke. 2004; 35(6):1316-22. DOI: 10.1161/01.STR.0000126827.69286.90. View

18.

Lorente L, Martin M, Lopez P, Ramos L, Blanquer J, Caceres J . Association between serum tissue inhibitor of matrix metalloproteinase-1 levels and mortality in patients with severe brain trauma injury. PLoS One. 2014; 9(4):e94370. PMC: 3984169. DOI: 10.1371/journal.pone.0094370. View

19.

Crespo A, Brondani da Rocha A, Jotz G, Schneider R, Grivicich I, Pinheiro K . Increased serum sFas and TNFalpha following isolated severe head injury in males. Brain Inj. 2007; 21(4):441-7. DOI: 10.1080/02699050701311125. View

20.

Ghajar J . Traumatic brain injury. Lancet. 2000; 356(9233):923-9. DOI: 10.1016/S0140-6736(00)02689-1. View